Overview

A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis

Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, randomized, double-blind, parallel group, placebo controlled, multicenter study to evaluate the safety and efficacy of Rituximab in adults with RRMS.
Phase:
Phase 2
Details
Lead Sponsor:
Genentech, Inc.
Treatments:
Rituximab